Cancer combo trial pulled before it even started
NCT ID NCT06152523
First seen Apr 08, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study was designed to test a combination of two experimental drugs, monalizumab and MEDI5752, in people with metastatic cancers that have a specific genetic feature called MSI or dMMR. The goal was to see if the combination could shrink tumors. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of medical oncology - Saint-Antoine Hospital
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.